Oncolytics Biotech Inc T.ONC

CellPress: Emerging Field of OV Based Cancer Immunotherapy

[Noteable]

November 17, 2022 - https://www.cell.com/trends/cancer/pdf/S2405-8033(22)00223-0.pdf

For the barking dogs ... ONCY's pelareorep is demonstrating leadership in the emerging field of oncolytic virus based cancer immunotherapy

[Noteable]

Very apparently "Oncolytic viruses were a hot topic at SITC 2022 thanks to combinations with checkpoint inhibitors." David Schull (@davidschull) / Twitter https://twitter.com › davidschull     Nov 16, 2022

[Noteable]

Oncolytics Biotech Presents Updated Clinical Data at SITC ... https://www.finanznachrichten.de › nachrichten-2022-11     Nov 10, 2022 — Data support Oncolytics' plan to advance its pancreatic cancer program ... an inflamed tumor phenotype -- turning "cold" 

[Noteable]

The oncolytic virus reovirus (pelareorep) has demonstrated that it can convert cold tumors into "hot" tumor by overcoming a hostile (hypoxic) tumor microenvironment (TME) and turning such a hostile TME into one that is more conducive for treatment with immune checkpoint inhibitors, like Roche's atezolizumab (Tecentriq), or Merck KGaA/Pfier's avelumab (Bavencio), or Incyte's

[Noteable]

Should read ....  Aligned with this prior research, Hotani et al. demonstrated that at 120 h post-systemic administration of reovirus (pelareorep), HIF-1 and its target genes were down-regulated. In addition, they inactivated reovirus by UV and observed that the HIF-1 protein level was not altered, proposing that HIF-1 down-regulation was dependent on reovirus replication. 

[Noteable]

Also, as solid tumors progress and outstrip the oxygen supply, large areas in the TME often become hypoxic owing to aberrant vacularization and poor blood supply. The hypoxic TME induces metabolic dysfunction in T cells, negatively affecting the T-cell proliferation and effector function and inducing mitochondrial damage that promotes T-cell exhaustion. ONCY's pelareorep has demonstrated

[Noteable]

Almost all solid tumors displaying hypoxic areas in the tumor microenvironment (TME) are associated with therapeutic failure. It is now well established that the abnormal growth of malignant solid tumors exacerbates their susceptibility to hypoxia. Cold tumors are typically hypoxic which manifest an immunosuppressive (hostile) TME. Therefore, having the ability to target hypoxia, convert an

[Noteable]

Hypoxia, a condition of insufficient oxygen availability, frequently occurs in solid tumors because of their high oxygen/nutrient demand and abnormal tumor vasculature resulting in a hypoxic TME and stimulation of hypoxia-inducible factor (HIF-1) signaling-in the metastatic cascade. The systemic administration of ONCY's pelareorep results in the down-regulation of HIF-1 and the conversion of

[Noteable]

More specifically, HIF-1α is related to other variables with a more consolidated predictive and prognostic value on outcome and all these variables are associated with a more aggressive and hypoxic tumor microenvironment.  ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signalling and by doing so is able to convert an otherwise aggressive and

[Noteable]

Many oncolytic viruses are currently being tested as potential cancer therapeutic agents. To be effective, these viruses must replicate and propagate efficiently through the tumor mass. However, it has been demonstrated that the hypoxia that characterizes many tumors is an obstacle to viral therapy because of its inhibition of viral replication and propagation in an immunosuppressive tumor

[Noteable]

For those intent on casting shawdows on company accomplishements, I have already referenced that in the chalenge of overcoming the hypoxia that characterizes solid tumors and a hostile TME, ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signaling, resulting in HIF-1α inhibition, and by doing so is able to convert an otherwise aggressive and hypoxic

[Noteable]

Should read ... "For those intent on casting shadows .... "

[Noteable]

I have already posted that in the challenge of overcoming the hypoxia that characterizes solid tumors and a hostile TME, ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signaling, resulting in HIF-1α inhibition, and by doing so is able to convert an otherwise aggressive and hypoxic tumor microenvironment (TME) into one that can promote T cell

[Noteable]

Barking dogs are out trying to create noise to drown out rational and relevant information.

[Noteable]

For further clarification ....  There are two types of hypoxic conditions. First, diffusion-limited hypoxia or chronic hypoxia leads to inhibition of cell proliferation in cancer regions with low oxygen concentration and the hypoxic microenvironment is a major limitation that affects the efficacy of many oncolytic viruses, other than reovirus (pelareorep)....The other form is acute

[yureja42]

This post has been removed in accordance with Community Policy

[Noteable]

And for further due diligence is the following post: I have already posted that in the challenge of overcoming the hypoxia that characterizes solid tumors and a hostile TME, ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signaling, resulting in HIF-1α inhibition, and by doing so is able to convert an otherwise aggressive and hypoxic tumor

[9mmmm]

[Noteable]

Reposted for new-comer due diligence : I have already posted that in the challenge of overcoming the hypoxia that characterizes solid tumors and a hostile TME, ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signaling, resulting in HIF-1α inhibition, and by doing so is able to convert an otherwise aggressive and hypoxic tumor microenvironment (TME

[Noteable]

Reovirus (pelareorep) reduces HIF-1α expression in hypoxic tumor fractions, contributing to the overall oncolytic effect by reducing transcription of HIF1α-responsive genes including VEGF and those responsible for maintaining cancer stem cell phenotypes.  HIF-1α is a strong inducer of CD39, CD38 and the A2Rs that are key mediators of extracellular adenosine signaling in the TME, thus

[Noteable]

Upon the following understanding of ONCY's pelareorep's mechanism of action, reovirus (pelareorep) reduces HIF-1α expression in hypoxic tumor fractions, contributing to the overall oncolytic effect by reducing transcription of HIF1α-responsive genes including VEGF and those responsible for maintaining cancer stem cell phenotypes.  HIF-1α is a strong inducer of CD39, CD38 and the

[yureja28]

This post has been removed in accordance with Community Policy

[Noteable]

November 30, 2022 - USA NewsGroup  Promotional Fact sheet. https://usanewsgroup.com/2020/02/24/why-biotechnology-companies-are-so-important/

[Noteable]

Repost:  November 17, 2022 - https://www.cell.com/trends/cancer/pdf/S2405-8033(22)00223-0.pdf For the barking dogs ... ONCY's pelareorep is demonstrating leadership in the emerging field of oncolytic virus based cancer immunotherapy

[Davepark5]

Ok Noteable seems to have a few screws loose.  Maybe canadafan? westcoast? kws?  Any thoughts on why we are down?

[Normandt]

Do you know why you are here ?   You seem completely lost.

[Noteable]

Who are you talking about Normandt? Which barking dog are you asking?

[Noteable]

OK Normandt .. I see ... it's the new and most recent barking dog .. DavidParker or whatever loosescrew he calls himself.

[Kswdelux]

We are down because ONC/ONCY shares are heavily manipulated. I have stated this before many times. This has been going on for years. At least 18 years, and more so more volitile in the past 2 years. When ever there is any increase in volume, like going into up coming news, the volume increases on speculation and the SP climbs as it is harder to manipulate a stock going into coming NRs, plus

[westcoast1000]

KSW, Thanks for this wise and thoughtful post. I agree with you completely. Probably that is because we have watched the same events for the last 10 years or so. Just wait. Ignore the current S/P The Goblet results and indisputable, as illustrated by Fast Track Designation. Bracelet only has to look as good as it did last time to confirm those results, which got us our first fast track. All

[westcoast1000]

...are indisputable.

[Capitalista]

Excellent post, Ksw - thanks!  A bit of rationality in this babel of shrill and baseless ululations

[Quentin30]

when does the book come out... jeez...  were the moon landings faked aswell kswdelux..? Yup I agree folk should stop complaining about daily price fluctations and short term gains.. But oh, hang on. how long does one wait for gains... more than 24 years..? shall we give ONCY another ten... well, if you wait till phase III approval... that now does not seem likely until 2028... IF ONCY

[Lesalpes29]

[Lesalpes29]

We all know Quentin that you shorted the stock and you want to cover. Close your fricking mouth!

[Buckhenry]

down 12% in pre market... how you want to spin this pumpers???

[canadafan]

I'm puzzled. The 7am Central time, presentation should be done. no news. Perhaps they are waiting for the 5pm abstract. That would certainly be after market close. The San Antonio symposium talks about information embargo. Not clear , what they mean by " after presentation". regardless. We will know more by end of Tomorrow. does anyone have access to the abstracts?

[Noteable]

As already posted and in advance of today's presentation ..ONCY's pelareorep is demonstrating leadership in the emerging field of oncolytic virus based cancer immunotherapy Previous data from the AWARE-1 study demonstrated that addition of atezolizumab (atezo) to pela increased the CelTIL score (study’s primary endpoint) by more than 30% in 60% of HR+/HER2- early breast cancer